Table 3

Relationship between HLA-DRB1 allele carrier status and anticitrullinated protein/peptide autoantibody status in French patients with early rheumatoid arthritis

Carrier status

Odds ratio (95% confidence interval)

P

P for trend

Yes

No

S1 carrier

CCP2-positive

32 (57.1)

78 (75.0)

0.44 (0.21–0.94)

0.0312

0.0134

CCP2-negative

24 (42.9)

26 (25.0)

AhFibA-positive

31 (55.4)

77 (74.0)

0.43 (0.21–0.91)

0.0213

0.0113

AhFibA-negative

25 (44.6)

27 (26.0)

CCP2-positive

CCP2-negative

49 (83.1)

61 (60.4)

3.21 (1.39–7.9)

0.0028*

0.0049*

AhFibA-positive

10 (16.9)

40 (39.6)

AhFibA-negative

50 (84.8)

58 (57.4)

4.12 (1.75–10.49)

0.0004*

0.0003*

CCP2-positive

9 (15.2)

43 (42.6)

S3P carrier

CCP2-positive

61 (79.2)

49 (59.0)

2.65 (1.24–5.74)

0.0066*

0.0014*

CCP2-negative

16 (20.8)

34 (41.0)

AhFibA-positive

61 (79.2)

47 (56.6)

2.92 (1.38–6.32)

0.0025*

0.0035*

AhFibA-negative

16 (20.8)

36 (43.4)

S3D carrier

CCP2-positive

17 (45.9)

93 (75.6)

0.27 (0.12–0.63)

0.0011*

0.0009*

CCP2-negative

20 (54.1)

30 (24.4)

AhFibA-positive

19 (51.4)

89 (72.4)

0.4 (0.18–0.93)

0.0266

0.0145

AhFibA-negative

18 (48.6)

34 (27.6)

Data presented as n (%). Status for anticyclic citrullinated peptides (anti-CCP2) antibodies or antideiminated human fibrinogen autoantibodies (AhFibA) among 160 patients with early rheumatoid arthritis, carrying the different HLA-DRB1 alleles encoding the shared epitope classified into four groups according to the new classification. Odds ratios, 95% alpha-risk confidence interval and P value for exact Fisher test. The dose effect was investigated for alleles positively or negatively associated with immunological markers using tests for trend of the log odds. *Significant after correcting for multiple testing according to the Benjamini–Yekutieli 2001 method at an overall critical P value of 5%.

Gourraud et al. Arthritis Research & Therapy 2007 9:R27   doi:10.1186/ar2131